Galectin Therapeutics Inc. (GALT)

[thefamilyman]

I was hoping that the company's previous management problems were addressed by the canning of Czirr. But the statement you quoted is a slap in the face for existing shareholders. It's incredible that Traber thinks it's OK to fund such a useless trial with our money.

I think it's time to hire a grownup to run this company.

Great job, Traber, not only screw over your drug development and shareholders by designing a trial based on measurement techniques where you have no prior data but then make the failure into two technical papers where you say:

“While these three imaging methods are approved for diagnostic use and are currently available to physicians, they have not been used in prospective, therapeutic clinical trials to assess drug efficacy in NASH,” said Peter Traber, M.D., president, chief executive officer and chief medical officer of Galectin Therapeutics and co-investigator of both studies. “We at Galectin Therapeutics are taking the opportunity in our Phase 2 trials, NASH-FX and NASH-CX, to validate and better understand utility of these non-invasive testing methods for use in future clinical trials and drug approvals, adding tremendous momentum in this area of medicine.”

How about protecting shareholder value as your first priority? - biotech2010